Aldred Gregory G, Rooney Timothy P C, Willems Henriette M G, Boffey Helen K, Green Christopher, Winpenny David, Skidmore John, Clarke Jonathan H, Andrews Stephen P
The ALBORADA Drug Discovery Institute, University of Cambridge Island Research Building, Cambridge Biomedical Campus, Hills Road Cambridge CB2 0AH UK
RSC Med Chem. 2023 Aug 23;14(10):2035-2047. doi: 10.1039/d3md00355h. eCollection 2023 Oct 18.
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are therapeutic targets for diseases such as cancer, neurodegeneration and immunological disorders as they are key components in regulating cell signalling pathways. In an effort to make probe molecules available for further exploring these targets, we have previously reported PI5P4Kα-selective and PI5P4Kγ-selective ligands. Herein we report the rational design of PI5P4Kα/γ dual inhibitors, using knowledge gained during the development of selective inhibitors for these proteins. ARUK2007145 (39) is disclosed as a potent, cell-active probe molecule with ADMET properties amenable to conducting experiments in cells.
磷脂酰肌醇5-磷酸4-激酶(PI5P4Ks)是癌症、神经退行性疾病和免疫紊乱等疾病的治疗靶点,因为它们是调节细胞信号通路的关键组成部分。为了获得可用于进一步探索这些靶点的探针分子,我们之前报道了PI5P4Kα选择性和PI5P4Kγ选择性配体。在此,我们利用在开发这些蛋白的选择性抑制剂过程中获得的知识,报道了PI5P4Kα/γ双重抑制剂的合理设计。ARUK2007145(39)被披露为一种具有细胞活性的强效探针分子,其吸收、分布、代谢、排泄和毒性(ADMET)特性适合在细胞中进行实验。